DK2684056T3 - Method for monitoring anticoagulant therapy - Google Patents
Method for monitoring anticoagulant therapy Download PDFInfo
- Publication number
- DK2684056T3 DK2684056T3 DK12748059.8T DK12748059T DK2684056T3 DK 2684056 T3 DK2684056 T3 DK 2684056T3 DK 12748059 T DK12748059 T DK 12748059T DK 2684056 T3 DK2684056 T3 DK 2684056T3
- Authority
- DK
- Denmark
- Prior art keywords
- plasma
- factor
- coagulation
- test
- fiix
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (14)
1. Fremgangsmåde til måling af aktiviteten af et vitamin K-antagonist-antikoagulationslægemiddel i en patient, og som er baseret på måling af kombineret aktivitet af både og kun koagulationsfaktorerne II og X i en testplasmaprøve fra patienten, hvilken fremgangsmåde omfatter: - blanding af testplasmaprøven med plasma, som kun mangler faktor II og faktor X, hvori forholdet mellem testplasmaprøven og mangelplasmaet er i intervallet fra 1:1 til 1:20, - tilsætning til testplasmaprøven af et eller flere koagulationsreagenser og calcium, og - bestemmelse af blodstørkningsevnen ved måling af blodstørkningstid eller thrombindannelse.
2. Fremgangsmåde ifølge krav 1, hvori det ene eller flere koagulationsreagenser er valgt fra gruppen bestående af: i) thromboplastin, ii) phospholipider, i i i) faktor IXa, iv) faktor Xla, v) faktor Xlla, vi) kallikrein, vii) exogen aktivator, inklusive slangegifte, som aktiverer faktor X, og viii) faktor Vila.
3. Fremgangsmåde ifølge krav 2, omfattende tilsætning af en kontaktaktivator valgt fra gruppen bestående af i) kaolinpartikler, ii) celit, iii) glaspartikler, iv) silicapartikler og v) ellaginsyre.
4. Fremgangsmåde ifølge ethvert af de foregående krav, som yderligere omfatter trinnet fortynding af testplasmaprøven med puffer eller saltopløsning.
5. Fremgangsmåde ifølge ethvert af de foregående krav, hvori koagulationsreagenset er fortyndet med vand, en vandig saltopløsning eller en pufret, vandig opløsning.
6. Fremgangsmåde ifølge ethvert af kravene 1 til 5, hvori mindst en komponent af koagulationsreagenset, mangelplasma eller calciumkilde er frysetørret, og hvori fremgangsmåden yderligere omfatter et trin til rekonstituering af denne mindst ene komponent.
7. Fremgangsmåde ifølge ethvert af kravene 1 til 6, hvori trinnet til bestemmelse af blodstørkningsevne omfater en fremgangsmåde valgt fra gruppen bestående af: - manuel/visuel koagulationsdetektion, - mekaniske og/eller elektroniske metoder til at observere viskositetsændringer, - optiske metoder til detektion af clotdannelse, - kromogen detektion under anvendelse af kromogene substrater, - fluorogen detektion under anvendelse af fluorogene substrater, og - luminogen detektion.
8. Testkit til måling af aktiviteten af et vitamin K-antagonist-antikoagulationslægemiddel i en patient, omfattende: - et koagulationsreagens, og - normal plasma, som kun mangler faktor II og faktor X, og som indeholder andre faktorer, inklusive faktor VII og IX (Fiix-deficient plasma), og - eventuelt omfattende en calciumionkilde.
9. Testkit ifølge krav 8 omfattende i en beholder koagulationsreagenset og det Fiix-deficiente plasma.
10. Testkit ifølge krav 8 eller 9 omfattende en første beholder omfattende koagulationsreagenset og det Fiix-deficiente plasma.
11. Testkit ifølge krav 8 omfattende i en første beholder koagulationsreagenset og i en anden beholder det Fiix-deficiente plasma.
12. Testkit ifølge ethvert af kravene 8 til 11, hvori koagulationsreagenset er valgt fra en eller flere af i) thromboplastin, ii) phospholipider, iii) faktor IXa, iv) faktor Xla, v) faktor Xlla, vi) kallikrein, vii) exogen aktivator, inklusive slangegifte, som aktiverer faktor X, og viii) faktor Vila.
13. Testkit ifølge krav 12, hvori koagulationsreagenset omfatter phospholipider, hvori kittet omfatter i en beholder koagulationsreagenset, en kontaktaktivator som beskrevet i krav 4, og Fiix-deficient plasma.
14. Testkit ifølge ethvert af kravene 8 til 13, hvori koagulationsreagenset og/eller det Fiix-deficiente plasma er frysetørret.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS050010A IS2809B (is) | 2011-03-08 | 2011-03-08 | Blóðstorkumæling |
| PCT/IS2012/050005 WO2012120546A2 (en) | 2011-03-08 | 2012-03-08 | Method for monitoring anticoagulant therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2684056T3 true DK2684056T3 (da) | 2017-07-10 |
Family
ID=46682867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12748059.8T DK2684056T3 (da) | 2011-03-08 | 2012-03-08 | Method for monitoring anticoagulant therapy |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9234902B2 (da) |
| EP (1) | EP2684056B1 (da) |
| CN (1) | CN103534595B (da) |
| DK (1) | DK2684056T3 (da) |
| ES (1) | ES2636318T3 (da) |
| IN (1) | IN2013MN01890A (da) |
| IS (1) | IS2809B (da) |
| RU (1) | RU2607658C2 (da) |
| WO (1) | WO2012120546A2 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11181534B2 (en) | 2014-04-04 | 2021-11-23 | Bloodworks | Routine laboratory and point-of-care (POC) testing for hemostasis |
| CN106574922B (zh) * | 2014-05-05 | 2020-06-05 | 美国血液技术公司 | 用于检测纤维蛋白溶解和纤溶亢进的方法学和试剂 |
| SE540132C2 (sv) * | 2014-05-22 | 2018-04-10 | Zafena Ab | Analysmetod för bestämning av antikoagulanter i blod eller blodplasma |
| CN106461327B (zh) | 2014-06-09 | 2019-12-13 | 泰尔茂比司特公司 | 冻干法 |
| JP6871673B2 (ja) * | 2015-03-31 | 2021-05-12 | 学校法人東日本学園 | 血液検体を判定するための方法、装置及びコンピュータプログラム、並びに血液検体分析装置 |
| US11480559B2 (en) * | 2016-01-07 | 2022-10-25 | Fujimori Kogyo Co., Ltd. | Blood collection tube, reagent, and method for analyzing blood characteristics using same |
| RU2655302C1 (ru) * | 2017-05-15 | 2018-05-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования эффективности антикоагулянтной терапии у больных с фибрилляцией предсердий, перенесших инсульт |
| RU2660706C1 (ru) * | 2017-09-26 | 2018-07-09 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ПМ" Минздрава России) | Скрининг-тест определения контактного пути коагуляции (СТОКПК) |
| WO2019074886A1 (en) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | LYOPHILIZATION CONTAINER AND METHOD OF USE |
| CN109459420B (zh) * | 2018-12-29 | 2021-06-04 | 华南师范大学 | 一种水体中二/三价铁离子的检测方法 |
| US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| CN110361531B (zh) * | 2019-08-02 | 2023-04-11 | 天津医科大学总医院 | 一种检测微粒促凝活性的实验方法 |
| CN114778858A (zh) * | 2022-06-23 | 2022-07-22 | 深圳市帝迈生物技术有限公司 | 一种狼疮抗凝物检测试剂盒 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL238873A (da) * | 1958-05-16 | |||
| US3395210A (en) * | 1964-02-07 | 1968-07-30 | Warner Lambert Pharmaceutical | Lyophilized diagnostic reagent for the determination of blood coagulation factors |
| AT350726B (de) * | 1976-08-30 | 1979-06-11 | Immuno Ag | Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma |
| DE3413311A1 (de) | 1984-04-09 | 1985-10-17 | Behringwerke Ag, 3550 Marburg | Reagenz zur bestimmung der thromboplastinzeit |
| WO1993007491A1 (en) | 1991-10-04 | 1993-04-15 | Board Of Regents Of The University Of Nebraska | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
| US5447440A (en) * | 1993-10-28 | 1995-09-05 | I-Stat Corporation | Apparatus for assaying viscosity changes in fluid samples and method of conducting same |
| US6194394B1 (en) | 1998-07-01 | 2001-02-27 | Sigma-Aldrich Co. | Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays |
| EP0984280A1 (en) * | 1998-09-03 | 2000-03-08 | Sysmex Corporation | Anticoagulant and hemanalysis method |
| KR101154246B1 (ko) | 2003-05-16 | 2012-06-13 | 내셔날 인스티튜트 포 바이올로지칼 스탠다즈 앤 컨트롤 (엔아이비에스씨) | 활성화 혼합물 |
| CN1856710B (zh) * | 2003-09-22 | 2012-06-13 | 荷玛特克斯研究有限公司 | 测定促凝血磷脂的方法 |
| SE0303249D0 (sv) * | 2003-12-02 | 2003-12-02 | Inst Polymerutveckling Ab | Hematocrit and analyte concentration determination |
| CN1952169B (zh) * | 2005-10-18 | 2010-05-12 | 上海太阳生物技术有限公司 | 临床检验凝血酶原时间(pt)测定体外诊断试剂盒 |
| CN101221189B (zh) * | 2007-01-12 | 2012-08-15 | 上海太阳生物技术有限公司 | 一种用于测定活化部分凝血活酶时间aptt的体外诊断试剂盒 |
| CN101526538B (zh) * | 2008-03-09 | 2014-04-09 | 上海长岛生物技术有限公司 | 液体白陶土aptt试剂 |
| EP2177624A1 (en) | 2008-10-02 | 2010-04-21 | Siemens Healthcare Diagnostics Products GmbH | Blood coagulation assays |
-
2011
- 2011-03-08 IS IS050010A patent/IS2809B/is unknown
-
2012
- 2012-03-07 US US13/414,112 patent/US9234902B2/en active Active
- 2012-03-08 IN IN1890MUN2013 patent/IN2013MN01890A/en unknown
- 2012-03-08 RU RU2013144950A patent/RU2607658C2/ru active
- 2012-03-08 CN CN201280021851.3A patent/CN103534595B/zh active Active
- 2012-03-08 DK DK12748059.8T patent/DK2684056T3/da active
- 2012-03-08 EP EP12748059.8A patent/EP2684056B1/en active Active
- 2012-03-08 ES ES12748059.8T patent/ES2636318T3/es active Active
- 2012-03-08 WO PCT/IS2012/050005 patent/WO2012120546A2/en active Application Filing
-
2015
- 2015-12-03 US US14/957,883 patent/US20160108457A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2636318T3 (es) | 2017-10-05 |
| EP2684056A2 (en) | 2014-01-15 |
| WO2012120546A2 (en) | 2012-09-13 |
| WO2012120546A3 (en) | 2012-11-29 |
| CN103534595B (zh) | 2016-03-09 |
| US20120231485A1 (en) | 2012-09-13 |
| RU2013144950A (ru) | 2015-04-20 |
| RU2607658C2 (ru) | 2017-01-10 |
| IN2013MN01890A (da) | 2015-09-25 |
| IS2809B (is) | 2012-10-15 |
| US20160108457A1 (en) | 2016-04-21 |
| EP2684056B1 (en) | 2017-05-03 |
| US9234902B2 (en) | 2016-01-12 |
| CN103534595A (zh) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2684056T3 (da) | Method for monitoring anticoagulant therapy | |
| AU757459B2 (en) | Inhibition of coagulation in blood and blood products | |
| JP3047120B2 (ja) | 活性化因子ｖｉｉに関する定量的凝血検定 | |
| CA2623142C (en) | Methods for a global assay of coagulation and fibrinolysis | |
| JP5628409B2 (ja) | 試験液の凝固特性を測定するための組成物 | |
| EP2952900A1 (en) | Diagnostic composition and its use in the determination of coagulation characteristics of a test liquid | |
| Lebreton et al. | Thrombin generation and cirrhosis: state of the art and perspectives | |
| US20150093770A1 (en) | Method and device for the determination of platelet function under flow conditions | |
| BR112014031509B1 (pt) | Para a determinação simultânea in vitro em tempo real do curso da atividade da enzima proteolítica e da resistência do coágulo de fibrina, reômetro rotativo e uso de um reômetro rotativo | |
| Gudmundsdottir et al. | Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time | |
| US20100227346A1 (en) | Activation Mixture | |
| US20110177541A1 (en) | Method for adjusting the coagulation time in calibrator or control plasmas | |
| CN109082458B (zh) | 一种血栓弹力图法定量检测口服凝血因子Xa抑制剂试剂盒及其制备方法 | |
| Foley et al. | Measuring the mechanical properties of blood clots formed via the tissue factor pathway of coagulation | |
| ES2377437T3 (es) | Procedimiento para determinar la actividad de coagulación total de una muestra de sangre o plasma | |
| EP2405274A1 (en) | Monitoring anticoagulant therapy and identifying reversible direct factor Xa inhibitors | |
| Asmis | Coagulation factor concentrates | |
| Mendelsohn et al. | Effects of platelets and platelet‐derived material on the activated partial thromboplastin time (Cephotest®) coagulation test | |
| Hellstern | Composition of plasma | |
| Hedner et al. | Recent advances in clot biology and assessment of clotting | |
| Ponjee et al. | One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application |